Palonosetron Fresenius Kabi (Palonosetron Hydrochloride)

Palonosetron Hydrochloride, the active ingredient in Palonosetron Fresenius Kabi, is a 5-HT3 receptor antagonist presented as a sterile injectable solution for intravenous use. It is employed to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients.

GNH USA supplies Palonosetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Palonosetron Fresenius Kabi is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting related to cancer therapy. It is indicated for: - Chemotherapy‑induced nausea and vomiting (CINV): Reduces the incidence and severity of acute and delayed CINV. - Post‑operative nausea and vomiting (PONV): Decreases the frequency of nausea and vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: Helps control nausea and vomiting associated with radiation treatment.

Adverse reactions to Palonosetron Fresenius Kabi are generally mild to moderate and are monitored during treatment.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Dizziness: sensation of light‑headedness. - Injection site erythema: redness at the site of administration.

Serious or Rare Side Effects: - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Serotonin syndrome: agitation, hyperreflexia, tremor, or fever. - Severe constipation or intestinal obstruction. - Pulmonary edema: fluid accumulation in the lungs. - Neuro‑muscular weakness: unexpected loss of muscle strength.

When using Palonosetron Fresenius Kabi, clinicians should consider several safety aspects.

- Assess  "); - Assess  ");  ...

The following  ...